Massimo Iavarone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8853361/publications.pdf

Version: 2024-02-01

280 papers 7,322 citations

76326 40 h-index 80 g-index

286 all docs 286 docs citations

286 times ranked 8909 citing authors

#	Article	IF	CITATIONS
1	The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut, 2010, 59, 638-644.	12.1	358
2	Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology, 2011, 54, 2055-2063.	7.3	321
3	Two-Band Superconductivity inMgB2. Physical Review Letters, 2002, 89, 187002.	7.8	306
4	Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients. Gastroenterology, 2007, 133, 1445-1451.	1.3	290
5	The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. Journal of Hepatology, 2009, 50, 746-754.	3.7	280
6	High rates of 30-day mortality in patients with cirrhosis and COVID-19. Journal of Hepatology, 2020, 73, 1063-1071.	3.7	279
7	Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology, 2005, 42, 1414-1419.	7.3	270
8	Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage Cirrhosis. Gastroenterology, 2013, 144, 1024-1030.	1.3	195
9	Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. Journal of Hepatology, 2018, 68, 485-492.	3.7	195
10	Unusual Strong-Coupling Effects in the Tunneling Spectroscopy of Optimally Doped and OverdopedBi2Sr2CaCu2O8+δ. Physical Review Letters, 1998, 80, 153-156.	7.8	187
11	Scanning Tunneling Spectroscopy in MgB2. Physical Review Letters, 2001, 86, 4374-4377.	7.8	185
12	Scanning Tunneling Microscopy Observation of a Square Abrikosov Lattice inLuNi2B2C. Physical Review Letters, 1997, 78, 4273-4276.	7.8	177
13	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell, 2016, 30, 879-890.	16.8	172
14	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncology, The, 2020, 21, 947-956.	10.7	166
15	Emergence of coherence in the charge-density wave state of 2H-NbSe2. Nature Communications, 2015, 6, 6313.	12.8	123
16	Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. Journal of Hepatology, 2013, 58, 1188-1193.	3.7	110
17	Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology, 2015, 62, 784-791.	7.3	110
18	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICEâ€1 study. International Journal of Cancer, 2014, 135, 1247-1256.	5.1	109

#	Article	IF	CITATIONS
19	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut, 2016, 65, 1754-1764.	12.1	108
20	Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. Journal of Hepatology, 2016, 64, 1217-1223.	3.7	104
21	Direct Observation of Geometrical Phase Transitions in Mesoscopic Superconductors by Scanning Tunneling Microscopy. Physical Review Letters, 2005, 95, 167002.	7.8	92
22	Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver International, 2013, 33, 771-779.	3.9	91
23	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology, 2013, 57, 1046-1054.	7.3	89
24	Assessing Tumor Angiogenesis. Cancer Research, 2004, 64, 4373-4377.	0.9	83
25	Guiding superconducting vortices with magnetic domain walls. Physical Review B, 2008, 77, .	3.2	81
26	Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 1183-1191.e7.	4.4	79
27	Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology, 2011, 53, 1549-1557.	7.3	77
28	Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. Journal of Hepatology, 2003, 39, 253-261.	3.7	75
29	The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. Journal of Hepatology, 2015, 63, 1118-1125.	3.7	74
30	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut, 2015, 64, 1296-1302.	12.1	70
31	Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation. Hepatology, 2010, 52, 1723-1730.	7.3	67
32	Influence of topological edge states on the properties of <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Al</mml:mi><mml:mo>/</mml:mo><mml:msub .<="" 2014,="" 89,="" b,="" devices.="" josephson="" physical="" review="" td=""><td>>> ⊲mml:m</td><td>o>8i</td></mml:msub></mml:math>	>> ⊲m ml:m	o> 8i
33	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. American Journal of Transplantation, 2019, 19, 3176-3184.	4.7	60
34	The clinical and pathogenetic significance of estrogen receptorâ€Î² expression in chronic liver diseases and liver carcinoma. Cancer, 2003, 98, 529-534.	4.1	54
35	Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. United European Gastroenterology Journal, 2018, 6, 1039-1048.	3.8	54
36	Imaging the spontaneous formation of vortex-antivortex pairs in planar superconductor/ferromagnet hybrid structures. Physical Review B, 2011, 84, .	3.2	49

#	Article	IF	CITATIONS
37	Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. Hepatology, 2020, 72, 1912-1923.	7.3	48
38	Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. Journal of Hepatology, 2022, 76, 302-310.	3.7	48
39	Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. Journal of Viral Hepatitis, 2007, 14, 133-139.	2.0	47
40	Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. European Journal of Gastroenterology and Hepatology, 2010, 22, 180-184.	1.6	47
41	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers, 2019, 11, 1689.	3.7	44
42	The combination of PIVKAâ€II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on longâ€term oral therapy. Liver International, 2020, 40, 1987-1996.	3.9	44
43	PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e75982.	2.5	42
44	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. Digestive and Liver Disease, 2018, 50, 1105-1114.	0.9	41
45	Effect of disorder inMgB2thin films. Physical Review B, 2005, 71, .	3.2	40
46	Effect of magnetic impurities on the vortex lattice properties in <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mrow><mml:mtext>NbSe</mml:mtext></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow< td=""><td>ı>2∹7mml</td><td>:mn9</td></mml:mrow<></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math>	ı> 2 ∹7mml	:mn9
47	Evolution of Metastable Defects and Its Effect on the Electronic Properties of MoS2 Films. Scientific Reports, 2018, 8, 6724.	3.3	40
48	Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation. Transplantation, 2020, 104, 568-574.	1.0	40
49	Transverse instabilities of multiple vortex chains in magnetically coupled <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mrow><mml:mil:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml< td=""><td>า>2ऀ∹/mml</td><td>:mñ⁸</td></mml<></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mil:mrow></mml:mrow></mml:msub></mml:mrow></mml:math>	า> 2ऀ∹ /mml	:mñ ⁸
50	Superconductor/ferromagnet bilayers: Influence of magnetic domain structure on vortex dynamics. Physical Review B, 2008, 77, .	3.2	37
51	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	4.9	36
52	In situ growth and superconducting properties of YNi2B2C thin films. Applied Physics Letters, 1996, 69, 118-120.	3.3	35
53	Evolution of the superconducting properties in <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mi>FeSe</mml:mi><mm mathvariant="normal">S<mml:mi>x</mml:mi></mm></mml:msub></mml:mrow></mml:math> . Physical Review B. 2015, 92.	l:mrow><1 3.2	nml:mn>1
54	Transarterial chemoembolization with drugâ€eluting beads is effective for the maintenance of the Milanâ€in status in patients with a small hepatocellular carcinoma. Liver Transplantation, 2015, 21, 1259-1269.	2.4	35

#	ARTICLE Evolution of the charge density wave state in Cu <mmi:math< th=""><th>IF</th><th>Citations</th></mmi:math<>	IF	Citations
55	xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"> <mml:msub><mml:mrow></mml:mrow><mml:mi>x</mml:mi></mml:msub> <mml:math>TiSe<mml:math> (mml:msub><mml:mrow></mml:mrow> xmlns:mml="http://www.w3.org/1998/Math/Math/ML" display="inline"><mml:msub><mml:mrow display="inline" xmlns:mml="http://www.w3.org/1998/Math/Math/ML"><mml:msub><mml:mrow xml:msub=""><mml:mrow td="" xml:m<="" xml:mrow=""><td>3.2</td><td>34</td></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></mml:math>	3.2	34
56	HBV Infection and Hepatocellular Carcinoma. Clinics in Liver Disease, 2013, 17, 375-397.	2.1	34
57	Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virusâ€related cirrhosis who attained sustained virological response. Liver International, 2017, 37, 1526-1534.	3.9	34
58	Tunable transport in magnetically coupled MoGe/Permalloy hybrids. Applied Physics Letters, 2008, 93, .	3.3	33
59	Management of hepatocellular carcinoma in the time of COVID-19. Annals of Oncology, 2020, 31, 1084-1085.	1.2	33
60	Transport properties of ZrN superconducting films. Physical Review B, 2000, 62, 13915-13918.	3.2	32
61	Role of antiviral treatment for HCC prevention. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 771-781.	2.4	31
62	Imaging of combined hepatocellularâ€cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. United European Gastroenterology Journal, 2019, 7, 69-77.	3.8	31
63	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 370-379.	7.7	31
64	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. Cancer Management and Research, 2021, Volume 13, 9379-9389.	1.9	31
65	<i>eNOS</i> polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget, 2016, 7, 27988-27999.	1.8	30
66	Relation between normal-state and superconductive properties of niobium sputtered films. Physical Review B, 1995, 52, 4473-4476.	3.2	29
67	Visualizing domain wall and reverse domain superconductivity. Nature Communications, 2014, 5, 4766.	12.8	28
68	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. Liver International, 2018, 38, 1624-1634.	3.9	25
69	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open, 2021, 6, 100330.	4.5	25
70	Nonlinear microwave properties of Nb3Sn sputtered superconducting films. Journal of Applied Physics, 1997, 82, 1736-1742.	2.5	23
71	Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Digestive and Liver Disease, 2011, 43, 875-80.	0.9	23
72	Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. Digestive and Liver Disease, 2013, 45, 43-49.	0.9	23

#	Article	IF	CITATIONS
73	Vortex-antivortex coexistence in Nb-based superconductor/ferromagnet heterostructures. Physical Review B, 2014, 89, .	3.2	23
74	ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers, 2019, 11, 1023.	3.7	23
75	A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. Journal of Hepatology, 2015, 63, 1323-1333.	3.7	22
76	Properties of YNi2B2C superconducting thin films. Physical Review B, 1997, 56, 934-939.	3.2	20
77	Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Annals of Hepatology, 2018, 17, 110-118.	1.5	20
78	Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World Journal of Gastroenterology, 2020, 26, 1888-1900.	3.3	20
79	Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging. Digestive Diseases, 2015, 33, 735-744.	1.9	19
80	Observation of superconducting vortex clusters in S/F hybrids. Scientific Reports, 2016, 6, 38557.	3.3	19
81	Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. Liver International, 2016, 36, 166-176.	3.9	19
82	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. Liver Transplantation, 2021, 27, 1767-1778.	2.4	19
83	Evidence of vortex jamming in Abrikosov vortex flux flow regime. Physical Review B, 2012, 86, .	3.2	18
84	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver International, 2021, 41, 2997-3008.	3.9	18
85	Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. United European Gastroenterology Journal, 2016, 4, 363-370.	3.8	16
86	Single and Double Side YBCO Thin Films for X-Band Microwave Filters and Devices. International Journal of Modern Physics B, 1999, 13, 1333-1337.	2.0	15
87	Directional scanning tunneling spectroscopy in MgB2. Physica C: Superconductivity and Its Applications, 2003, 385, 215-220.	1.2	15
88	The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. Antiviral Therapy, 2009, 14, 789-796.	1.0	15
89	Sorafenib-Induced Destructive Thyroiditis. Thyroid, 2010, 20, 1043-1044.	4.5	15
90	Vortex-core properties and vortex-lattice transformation in FeSe. Physical Review B, 2019, 99, .	3.2	15

#	Article	IF	Citations
91	Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis. Liver Cancer, 2020, 9, 744-755.	7.7	15
92	International and multicenter realâ€world study of sorafenibâ€treated patients with hepatocellular carcinoma under dialysis. Liver International, 2020, 40, 1467-1476.	3.9	15
93	Superconducting gap anisotropy of LuNi2B2Cthin films from microwave surface impedance measurements. Physical Review B, 2001, 64, .	3.2	14
94	MgB2: directional tunnelling and two-band superconductivity. Superconductor Science and Technology, 2003, 16, 156-161.	3.5	14
95	Characterization of off-axis MgB2 epitaxial thin films for planar junctions. Applied Physics Letters, 2005, 87, 242506.	3.3	14
96	The local effect of magnetic impurities on superconductivity in Co _{<i>x</i>} NbSe ₂ and Mn _{<i>x</i>} NbSe ₂ single crystals. Journal of Physics Condensed Matter, 2010, 22, 015501.	1.8	14
97	HBV-related HCC, clinical issues and therapy. Digestive and Liver Disease, 2011, 43, S32-S39.	0.9	14
98	Transport and tunneling measurements in superconducting YNi2B2C. Physica C: Superconductivity and Its Applications, 1995, 251, 379-382.	1.2	13
99	Risk of hepatocellular carcinoma in relation to ABO blood type. Digestive and Liver Disease, 2016, 48, 94-96.	0.9	13
100	The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections. Infection and Immunity, 2021, 89, e0037621.	2.2	13
101	Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Cancers, 2021, 13, 5797.	3.7	13
102	Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. Expert Opinion on Drug Safety, 2019, 18, 603-610.	2.4	12
103	Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World Journal of Hepatology, 2015, 7, 2053.	2.0	12
104	Magnetization properties and vortex phase diagram of Cu <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mrow></mml:mrow><mml:mi>x</mml:mi></mml:msub></mml:math> TiSe <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mrow< td=""><td>3.2</td><td>11</td></mml:mrow<></mml:msub></mml:math>	3.2	11
105	/> <mml:mn>2</mml:mn> single crystals. Physical Review B, 2013, 88, . Minimal increases of serum alphaâ€foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under longâ€term oral therapy. Liver International, 2019, 39, 1964-1974.	3.9	11
106	Prothrombin induced by vitamin K absence or antagonistâ€II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis Câ€related cirrhosis treated with directâ€acting antiviral agents. Alimentary Pharmacology and Therapeutics, 2022, 55, 350-359.	3.7	11
107	Outcome of liver cancer patients with SARSâ€CoVâ€2 infection: An International, Multicentre, Cohort Study. Liver International, 2022, 42, 1891-1901.	3.9	11
108	TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with directâ€acting antivirals. Journal of Viral Hepatitis, 2019, 26, 1233-1236.	2.0	10

#	Article	IF	Citations
109	Reply to: Correspondence on "High rates of 30-day mortality in patients with cirrhosis and COVID-19― Journal of Hepatology, 2020, 73, 1570-1571.	3.7	10
110	STM tunneling spectroscopic studies of YNdxBa2â^'x Cu3O7â^'Î thin films. Physical Review B, 2002, 65, .	3.2	9
111	85 Five years of sequential LAM TO LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma. Journal of Hepatology, 2006, 44, S38.	3.7	8
112	930 HIGH RISK OF RENAL IMPAIRMENT DURING LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IN PATIENTS WITH LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B. Journal of Hepatology, 2009, 50, S338-S339.	3.7	8
113	Microwave measurements of superconducting Nb/sub 3/Sn films by a microstrip resonator technique. IEEE Transactions on Applied Superconductivity, 1997, 7, 1772-1775.	1.7	7
114	The superconducting energy gap and vortex lattice structure in LuNi2B2C. Physica C: Superconductivity and Its Applications, 1997, 282-287, 355-358.	1.2	7
115	Superconducting properties of YNdBaCuO and NdBaCuO thin films deposited by dc sputtering. IEEE Transactions on Applied Superconductivity, 2001, 11, 3201-3204.	1.7	7
116	STM tunnelling spectroscopy in MgB2thin films: the role of band structure in tunnelling spectra. Superconductor Science and Technology, 2004, 17, S106-S111.	3.5	7
117	696 ADD ON ADEFOVIR PREVENTS THE EMERGENCE OF ADV RESISTANCE IN LAMIVUDINE-RESISTANT PATIENTS: A 4-YEAR STUDY. Journal of Hepatology, 2008, 48, S259.	3.7	7
118	Giant conductance anisotropy in magnetically coupled Ferromagnet-Superconductor-Ferromagnet structures. Applied Physics Letters, 2010, 96, 092513.	3.3	7
119	Vortex Confinement in Planar Superconductor/Ferromagnet Hybrid Structures. IEEE Transactions on Magnetics, 2012, 48, 3275-3279.	2.1	7
120	Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on longâ€term analogue therapy for hepatitis B. Alimentary Pharmacology and Therapeutics, 2018, 48, 431-439.	3.7	7
121	Pulmonary Resection for Metastasis of Hepatocellular Carcinoma Recurring After Liver Transplant: An Italian Multicenter Experience. Frontiers in Oncology, 2020, 10, 381.	2.8	7
122	Superconducting properties of LuNi2B2C films and junctions. Physica C: Superconductivity and Its Applications, 2000, 341-348, 757-758.	1.2	6
123	A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis. Journal of Viral Hepatitis, 2003, 10, 423-426.	2.0	6
124	Transarterial embolization with microspheres in the treatment of monofocal HCC. Digestive and Liver Disease, 2009, 41, 143-149.	0.9	6
125	Influence of Domain Width on Vortex Nucleation in Superconductor/Ferromagnet Hybrid Structures. Journal of Superconductivity and Novel Magnetism, 2015, 28, 1107-1110.	1.8	6
126	High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis. European Journal of Clinical Pharmacology, 2018, 74, 1089-1090.	1.9	6

#	Article	IF	CITATIONS
127	Pattern of progression of intrahepatic cholangiocarcinoma: Implications for secondâ€line clinical trials. Liver International, 2022, 42, 458-467.	3.9	6
128	Properties of ErNi2B2C superconducting thin films. Physica C: Superconductivity and Its Applications, 1999, 312, 1-6.	1.2	5
129	Microwave properties of RE–Ni2B2C (RE=Y, Er) superconducting thin films. Physica C: Superconductivity and Its Applications, 1999, 319, 141-149.	1.2	5
130	A simple and reliable system forin situdeposition of large-area double-sided, superconducting films. Superconductor Science and Technology, 2000, 13, 1441-1446.	3.5	5
131	44 The long-term outcome of HBeAg-Negative patients with cirrhosis treated with lamivudine monotherapy: A 5-year prospective cohort study. Journal of Hepatology, 2004, 40, 16-17.	3.7	5
132	448 Rescue treatment with adefovir dipivoxil in lamivudine resistant patients with chronic hepatitis B. Journal of Hepatology, 2004, 40, 132-133.	3.7	5
133	Adjustable Superconducting Anisotropy in Superconductor-Ferromagnet Bilayers. IEEE Transactions on Applied Superconductivity, 2009, 19, 3471-3474.	1.7	5
134	STM studies of Co _{<i>x</i>} NbSe ₂ and Mn _{<i>x</i>} NbSe ₂ . Journal of Physics: Conference Series, 2009, 150, 052073.	0.4	5
135	Visualizing Vortex Dynamics in Py/Nb Thin Film Hybrids by Low Temperature Magnetic Force Microscopy. Journal of Superconductivity and Novel Magnetism, 2012, 25, 2167-2171.	1.8	5
136	Low-temperature scanning tunneling microscopy and spectroscopy measurements of ultrathin Pb films. Superconductor Science and Technology, 2015, 28, 045003.	3.5	5
137	Doppler-scanning tunneling microscopy current imaging in superconductor-ferromagnet hybrids. Applied Physics Letters, 2016, 108, .	3.3	5
138	Reshape and secure HCC managing during COVIDâ€19 pandemic: A single centre analysis of four periods in 2020 versus 2019. Liver International, 2021, 41, 3028-3032.	3.9	5
139	Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5). Cancers, 2022, 14, 336.	3.7	5
140	STM investigation of BSCCO 2212 and borocarbide materials. Journal of Physics and Chemistry of Solids, 1998, 59, 2030-2033.	4.0	4
141	Extended X-ray Absorption Fine Structure spectroscopy in Co0.013NbSe2. Journal of Physics: Conference Series, 2010, 200, 012224.	0.4	4
142	Magnetic pinning in a superconducting film by a ferromagnetic layer with stripe domains. Superconductor Science and Technology, 2014, 27, 125002.	3.5	4
143	Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance. Annals of Hepatology, 2019, 18, 318-324.	1.5	4
144	Reâ^'Ni2B2C superconducting borocarbides: "ln situ―growth of thin films, transport and point contact spectroscopy. Journal of Low Temperature Physics, 1997, 107, 527-532.	1.4	3

#	Article	IF	CITATIONS
145	Synthesis and STM investigation of rare-earth superconducting borocarbides. Superconductor Science and Technology, 1998, 11, 169-172.	3.5	3
146	Hydrogen–steel interaction: relationship between variations of mechanical properties of AISI 304 steel and hydrogen content. International Journal of Hydrogen Energy, 2003, 28, 881-887.	7.1	3
147	Momentum-dependent scanning tunneling spectroscopy in MgB2. Physica C: Superconductivity and Its Applications, 2003, 388-389, 141-142.	1.2	3
148	Adjustable superconducting anisotropy in MoGe-Permalloy hybrids. Journal of Physics: Conference Series, 2009, 150, 052095.	0.4	3
149	Anisotropic transport properties in tiltedc-axis MgB2thin films. Superconductor Science and Technology, 2010, 23, 025012.	3.5	3
150	Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence. Journal of Hepatology, 2017, 67, 1355-1356.	3.7	3
151	Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3 year study. Journal of Hepatology, 2018, 68, 5529.	3.7	3
152	Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib Journal of Clinical Oncology, 2017, 35, e15666-e15666.	1.6	3
153	In situ film deposition of superconducting borocarbides. Nuovo Cimento Della Societa Italiana Di Fisica D - Condensed Matter, Atomic, Molecular and Chemical Physics, Biophysics, 1997, 19, 995-1001.	0.4	2
154	Superconductivity and Antiferromagnetic Order in ErNi2B2C Thin Films. Journal of Superconductivity and Novel Magnetism, 1998, 11, 707-712.	0.5	2
155	Hepatitis C virus genotype 1b, cirrhosis, and risk of hepatocellular carcinoma. Hepatology, 2007, 47, 357-357.	7.3	2
156	794 PROSPECTIVE STUDY OF DYSPLASTIC NODULES IN CIRRHOSIS: CORRELATION WITH CT VASCULAR PATTERN, HISTOLOGY AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2009, 50, S290-S291.	3.7	2
157	The spectroscopic signature of the Co magnetic state in Co _{<i>x</i>} NbSe ₂ superconducting single crystals. Superconductor Science and Technology, 2011, 24, 024010.	3.5	2
158	Anisotropic Superconductivity and Vortex Dynamics inÂMagnetically Coupled F/S and F/S/F Hybrids. Journal of Superconductivity and Novel Magnetism, 2011, 24, 905-910.	1.8	2
159	P1059 PORTAL HYPERTENSION BUT NOT HCC RISK IS ATTENUATED IN COMPENSATED CIRRHOTICS FOLLOWING 10 YEARS OF TREATMENT WITH NUCLEOS(T)IDE ANALOGS. Journal of Hepatology, 2014, 60, S429-S430.	3.7	2
160	Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. Liver International, 2015, 35, 2187-2193.	3.9	2
161	Anisotropic Superconducting Gaps and Boson Mode in FeSe 1â^'x S x Single Crystals. Journal of Superconductivity and Novel Magnetism, 2017, 30, 763-768.	1.8	2
162	Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival. Digestive and Liver Disease, 2018, 50, 49.	0.9	2

#	Article	IF	CITATIONS
163	Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject. Aids, 2018, 32, 1727-1729.	2.2	2
164	SAT-130-Incidence and outcome of portal vein thrombosis in 817 HBV and HCV compensated cirrhotic patients under antiviral treatment: a single center longitudinal study. Journal of Hepatology, 2019, 70, e687-e688.	3.7	2
165	Biliary Stones After Brain Dead Liver Transplantation Today: Rates, Risk Factors, Treatments, and Outcomes. Transplantation Proceedings, 2019, 51, 1939-1945.	0.6	2
166	Focus on Very Late Hepatocellular Carcinoma Recurring After Liver Transplantation: A Case Report and Literature Review. Transplantation Proceedings, 2019, 51, 2998-3000.	0.6	2
167	Congenital Hepatic Fibrosis as a Cause of Recurrent Cholangitis: A Case Report and Review of the Literature. Livers, 2021, 1, 132-137.	1.9	2
168	Diagnostic value of Lens culinaris agglutinin isoform 3 fraction (AFP-L3%) and des-gamma-carboxy prothrombin (DCP) for the diagnosis of hepatocellular carcinoma in cirrhotic patients Journal of Clinical Oncology, 2010, 28, 4119-4119.	1.6	2
169	SUPERCONDUCTING PROPERTIES OF LuNi2B2C THIN FILMS. International Journal of Modern Physics B, 2000, 14, 2743-2748.	2.0	1
170	Long-term outcome of hepatitis B in lamivudine-resistant cirrhotic patients. Journal of Hepatology, 2002, 36, 115.	3.7	1
171	Phase Diagram of Single Crystal MgB2. Journal of Low Temperature Physics, 2003, 131, 1237-1244.	1.4	1
172	Direct observation of vortex lattice transitions in mesoscopic superconducting single crystals using STM. Physica C: Superconductivity and Its Applications, 2006, 437-438, 127-131.	1.2	1
173	Switching of magnetic domains in Permalloy microstructures using two-dimensional electron gas. Applied Physics Letters, 2006, 89, 182513.	3.3	1
174	Prospective validation of AASLD guidelines for the early diagnosis of hepatocellular carcinoma in cirrhotic patients. Digestive and Liver Disease, 2008, 40, A22-A23.	0.9	1
175	389 LOW RISK OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION: A 3-YEAR FOLLOW-UP STUDY IN 78 PATIENTS WITH CHRONIC HEPATITIS B. Journal of Hepatology, 2008, 48, S151.	3.7	1
176	912 PROGRESSIVE DECLINE OF HBsAg TITERS IN LONG-TERM VIROLOGICAL RESPONDERS TO NUCLEOS(T)IDE ANALOGUE THERAPY FOR CHRONIC HEPATITIS B. Journal of Hepatology, 2009, 50, S331.	3.7	1
177	O071 : Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in nash. Journal of Hepatology, 2015, 62, S226.	3.7	1
178	ENOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS Study. Digestive and Liver Disease, 2016, 48, e23.	0.9	1
179	Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. Digestive and Liver Disease, 2017, 49, e19.	0.9	1
180	Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: A single-center prospective 3-year study. Digestive and Liver Disease, 2018, 50, 36.	0.9	1

#	Article	IF	Citations
181	Liver transplant for hepatocellular carcinoma: A heavyweight therapeutic option in need of a new policy on liver graft allocation. Digestive and Liver Disease, 2018, 50, 1351-1352.	0.9	1
182	Liver Transplantations and Brain Dead Donors With Alcohol Abuse. Transplantation Proceedings, 2018, 50, 3105-3110.	0.6	1
183	Outbreak of acute hepatitis A involving young men in Lombardy Region, Italy: risk factors, clinical and virological characteristics. Journal of Hepatology, 2018, 68, S33.	3.7	1
184	Metastable defects in monolayer and few-layer films of MoS2. AIP Conference Proceedings, 2018, , .	0.4	1
185	FRI-376-Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival. Journal of Hepatology, 2019, 70, e560-e561.	3.7	1
186	Safety and effectiveness of Regorafenib in recurrent HCC after liver transplantation and progression on Sorafenib: a real-life multicentre study. Digestive and Liver Disease, 2019, 51, e12.	0.9	1
187	Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct acting antivirals: a 3-year study in 509 patients. Digestive and Liver Disease, 2019, 51, e67.	0.9	1
188	Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19. Gut, 2021, 70, 1798-1799.	12.1	1
189	Chemoembolization with epirubicin drug-eluting beads (DEB-TACE) to treat early and intermediate hepatocellular carcinoma Journal of Clinical Oncology, 2010, 28, 4141-4141.	1.6	1
190	Synthesis and microwave properties of thin films of the 1:2:2:1 borocarbide superconductors YNiBC and ErNiBC. IEEE Transactions on Applied Superconductivity, 1999, 9, 2394-2397.	1.7	0
191	<title>Excimer laser ablation of borocarbide targets</title> ., 2000,,.		0
192	ON THE ROLE OF Nd/Ba DISORDER ON THE SUPERCONDUCTING PROPERTIES OF Re1(NdxBa2-x)Cu3O7-Î′ (Re=Nd, Y) THIN FILMS. International Journal of Modern Physics B, 2000, 14, 2737-2742.	2.0	0
193	Monitoring serum HBV-DNA during lamivudine therapy by quantitative PCR assay may predict development of YMDD mutants. Gastroenterology, 2000, 118, A1461.	1.3	0
194	Study of hepatitis B virus X protein (HBx) mutants and quantification of HBV-DNA in tumorous and non-tumorous hepatocytes using laser capture microdissection (LCM). Journal of Hepatology, 2002, 36, 84-85.	3.7	0
195	Surface impedance of R1(NdxBa2â^'x)Cu3O7â^'Î' (R=Nd, Y) thin films. Physica C: Superconductivity and Its Applications, 2002, 372-376, 703-705.	1.2	0
196	Rescue treatment with adefovir dipivoxil for lamivudine resistant patients pre- and post- liver transplantation. Gastroenterology, 2003, 124, A709-A710.	1.3	0
197	Genotypic analysis of YMDD locus of HBV in patients responding to lamivudine monotherapy. Journal of Hepatology, 2003, 38, 180.	3.7	0
198	251 Increased expression of vascular endothelial growth factor and its receptor in hepatocellular carcinoma and extra-tumoral cirrhotic tissues. Journal of Hepatology, 2004, 40, 79.	3.7	0

#	Article	IF	CITATIONS
199	69 Local circulation of VEGF is involved in collateral vessels development in cirrhotic patients with portal hypertension. Journal of Hepatology, 2006, 44, S31.	3.7	0
200	STM Observation of Vortex Lattice Transitions in Superconducting Single Crystals with Periodic Pinning Arrays. AIP Conference Proceedings, 2006, , .	0.4	0
201	The Role of Hepatic Venous Pressure Gradient in Hepatitis C Virus Compensated Cirrhosis. Gastroenterology, 2007, 133, 2076.	1.3	O
202	Prospective evaluation of staging systems for hepatocellular carcinoma detected during surveillance of cirrhotic patients. Digestive and Liver Disease, 2007, 39, A39.	0.9	0
203	PA.102 VERY EARLY ADD-ON ADEFOVIR THERAPY IN PATIENTS WITH SUB-OPTIMAL VIROLOGICAL RESPONSE TO LAMIVUDINE. Digestive and Liver Disease, 2008, 40, S112.	0.9	0
204	PA.103 LOW RISK OF HEPATITIS B REACTIVATION IN PATIENTS WITH CHRONIC HEPATITIS C AND CONCURRENT INACTIVE HEPATITIS B INFECTION TREATED WITH INTERFERON AND RIBAVIRIN. Digestive and Liver Disease, 2008, 40, S112.	0.9	0
205	916 ENTECAVIR IS AN EFFECTIVE TREATMENT FOR NUC-NAIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: 48-WEEK DATA FROM A LARGE MULTICENTER COHORT STUDY. Journal of Hepatology, 2009, 50, S333.	3.7	0
206	CS.2.4 CONTRAST IMAGING TECHNIQUES CORRELATE WITH TUMOR GRADING IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. Digestive and Liver Disease, 2010, 42, S65.	0.9	0
207	OC.03.6 FIELD PRACTICE WITH SORAFENIB IN ADVANCED HCC: EFFECTIVENESS CONFIRMED, TOLERABILITY REDUCED BUT USUALLY MANAGEABLE, COMPARED TO REGISTRATION TRIALS. Digestive and Liver Disease, 2010, 42, S77.	0.9	О
208	P.132 CHEMOEMBOLIZATION WITH EPIRUBICIN DRUG ELUTING BEADS TO TREAT EARLY AND INTERMEDIATE HEPATOCELLULAR CARCINOMA. Digestive and Liver Disease, 2010, 42, S149-S150.	0.9	0
209	P.140 NATURAL HISTORY AND MULTIMODALITY TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA PROSPECTIVELY DETECTED IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. Digestive and Liver Disease, 2010, 42, S152.	0.9	O
210	P.142 THE NATURAL HISTORY OF HEPATIC MACROREGENERATIVE NODULES DEVELOPING IN CIRRHOTIC PATIENTS DURING SURVEILLANCE WITH ULTRASOUND (US). Digestive and Liver Disease, 2010, 42, S153.	0.9	0
211	35 THE NATURAL HISTORY OF HEPATIC MACROREGENERATIVE NODULES DEVELOPING IN CIRRHOTIC PATIENTS DURING SURVEILLANCE WITH ULTRASOUND (US). Digestive and Liver Disease, 2010, 42, S14.	0.9	O
212	T.N.21 DIAGNOSTIC YIELD AND STANDARDIZATION OF FINE NEEDLE BIOPSY IN THE CHARACTERIZATION OF LIVER NODULES IN CIRRHOTIC PATIENTS. Digestive and Liver Disease, 2010, 42, S22.	0.9	0
213	T.N.22 CONTRAST IMAGING TECHNIQUES CORRELATE WITH TUMOR GRADING IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. Digestive and Liver Disease, 2010, 42, S22-S23.	0.9	O
214	F.N.20 NATURAL HISTORY AND MULTIMODALITY TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA PROSPECTIVELY DETECTED IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. Digestive and Liver Disease, 2010, 42, S40.	0.9	0
215	F.N.22 FIELD PRACTICE WITH SORAFENIB IN ADVANCED HCC: EFFECTIVENESS CONFIRMED, TOLERABILITY REDUCED BUT USUALLY MANAGEABLE, COMPARED TO REGISTRATION TRIALS. Digestive and Liver Disease, 2010, 42, S41.	0.9	O
216	194 THE NATURAL HISTORY OF HEPATIC MACROREGENERATIVE NODULES DEVELOPING IN CIRRHOTIC PATIENTS DURING SURVEILLANCE WITH ULTRASOUND. Journal of Hepatology, 2010, 52, S84.	3.7	0

#	Article	IF	CITATIONS
217	229 NATURAL HISTORY AND MULTIMODALITY TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA PROSPECTIVELY DETECTED IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE. Journal of Hepatology, 2010, 52, S97.	3.7	0
218	OC-1 Prospective Italian multicenter field-practice study with sorafenib for advanced hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, S65.	0.9	0
219	F-35 Nucleos(t)ide analogues can be safely discontinued in chronic hepatitis B patients achieving HBsAg seroclearance. Digestive and Liver Disease, 2011, 43, S103.	0.9	О
220	753 NUCLEOS(T)IDE ANALOGUES CAN BE SAFELY DISCONTINUED IN CHRONIC HEPATITIS B PATIENTS ACHIEVING HBSAG SEROCLEARANCE. Journal of Hepatology, 2011, 54, S302-S303.	3.7	0
221	Dimensionality crossover in vortex dynamics of magnetically coupled F–S–F hybrids. Superconductor Science and Technology, 2011, 24, 024012.	3.5	0
222	716 PROGNOSTIC GENE-EXPRESSION SIGNATURE FOR HEPATITIS C-RELATED EARLY-STAGE LIVER CIRRHOSIS. Journal of Hepatology, 2012, 56, S283.	3.7	0
223	718 CONTRAST-ENHANCED CT SCAN DIFFERENTIATES HEPATOCELLULAR CARCINOMA AND INTRAHEPATIC CHOLANGIOCARCINOMA IN CIRRHOSIS. Journal of Hepatology, 2012, 56, S283-S284.	3.7	0
224	746 PROSPECTIVE VALIDATION OF 2010 AASLD GUIDELINE FOR THE DIAGNOSIS OF 1-2 CM HCC IN CIRRHOTIC PATIENTS. Journal of Hepatology, 2012, 56, S293-S294.	3.7	0
225	1008 SUSTAINED VIROLOGIC RESPONSE TO INTERFERON PREVENTS THE LETHAL CONSEQUENCE OF CLINICAL DECOMPENSATION IN PATIENTS WHO DEVELOP A HEPATOCELLULAR CARCINOMA POST ANTIVIRAL-TREATMENT. Journal of Hepatology, 2012, 56, S394.	3.7	O
226	Benign Liver Tumors. , 2012, , 1045-1060.		0
227	Reply:. Hepatology, 2012, 55, 1305-1306.	7.3	0
228	Re: Indeterminate 1-2 cm nodules found on hepatocellular carcinoma surveillance: Biopsy for all, some, or none?. Hepatology, 2012, 55, 651-651.	7.3	0
229	259 DETERMINANTS OF BLEEDING FROM ESOPHAGEAL VARICES IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB. Journal of Hepatology, 2013, 58, S110.	3.7	0
230	Reply to: "Non-invasive diagnosis of small nodules in cirrhosis― Journal of Hepatology, 2013, 59, 1361-1362.	3.7	0
231	722 LIVER STIFFNESS AND HEPATOCELLULAR CARCINOMA: IS IT REALLY USEFUL?. Journal of Hepatology, 2013, 58, S293.	3.7	0
232	P965 PERSONALIZED THERAPY WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2014, 60, S397.	3.7	0
233	P586 APPEARANCE OF COMBINED HEPATOCELLULAR CHOLANGIOCARCINOMA IN CIRRHOSIS AT CONTRAST ENHANCED IMAGING TECHNIQUES. Journal of Hepatology, 2014, 60, S265.	3.7	0
234	Appearance of combined hepatocellular cholangiocarcinoma in cirrhosis at contrast enhanced imaging techniques. Digestive and Liver Disease, 2014, 46, e17.	0.9	0

#	Article	IF	CITATIONS
235	First-line treatment of 90 consecutive HCC with drug eluting beads chemoembolization (DEB-TACE). Digestive and Liver Disease, 2014, 46, e64.	0.9	O
236	O123 POST SORAFENIB SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: THE ROLE OF TUMOR PROGRESSION AND LIVER IMPAIRMENT. Journal of Hepatology, 2014, 60, S51.	3.7	0
237	Post sorafenib survival in patients with advanced hepatocellular carcinoma: The role of tumor progression and liver impairment. Digestive and Liver Disease, 2014, 46, e35-e36.	0.9	O
238	Portal hypertension but not HCC risk is attenuated in compensated cirrhotics following 10 years of treatment with nucleos(t)ide analogs. Digestive and Liver Disease, 2014, 46, e50.	0.9	0
239	P0206: Prevention of bleeding following invasive procedures in cirrhotic patients: A single center experience. Journal of Hepatology, 2015, 62, S383.	3.7	O
240	Prevention of bleeding following invasive procedures in cirrhotic patients: A single center experience. Digestive and Liver Disease, 2015, 47, e10.	0.9	0
241	Hepatocellular carcinoma developing in European patients with prolonged HBV suppression: Biological and clinical features, and outcome. Digestive and Liver Disease, 2016, 48, e48-e49.	0.9	O
242	The role of serum alphafetoprotein determination in HCV-cirrhosis after antiviral treatment. Digestive and Liver Disease, 2016, 48, e54.	0.9	0
243	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. Digestive and Liver Disease, 2016, 48, e26.	0.9	O
244	Increased plasma levels of Von Willebrand factor (VWF) and Factor VIII (FVIII) during acute bacterial infection drive a pro-hemostatic imbalance and herald severe outcome in cirrhosis. Digestive and Liver Disease, 2016, 48, e13.	0.9	О
245	Accuracy of the Radiological Diagnosis of Hepatocellular Carcinoma outside the Periodic Surveillance with Ultrasound. Journal of Hepatology, 2016, 64, S335.	3.7	0
246	Prognostic Validation of Proposed BCLC-B Substaging System in Hepatocellular Carcinoma Patients Treated by Transarterial Chemoembolization. Journal of Hepatology, 2016, 64, S333.	3.7	0
247	Increased Plasma Levels of Von Willebrand Factor and Factor VIII (FVIII) During Acute Bacterial Infection Drive a Pro-Hemostatic Imbalance and Herald Severe Outcome in Cirrhosis. Journal of Hepatology, 2016, 64, S290-S291.	3.7	O
248	Multimodality Treatment of Hepatocellular Carcinoma: How Field Practice Complies with International Reccommendations. Journal of Hepatology, 2016, 64, S699.	3.7	0
249	Survival in patients with hepatocellular carcinoma and portal vein thrombosis. Digestive and Liver Disease, 2016, 48, e63.	0.9	0
250	Uncommon extrahepatic metastases from hepatocellular carcinoma. Hepatology, 2017, 66, 986-988.	7.3	0
251	Serum markers for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment. Digestive and Liver Disease, 2017, 49, e47.	0.9	O
252	Minimal increases of alpha-fetoprotein strongly predict HCC development in caucasian compensated HBV cirrhotics treated by entecavir or tenofovir: A 7-year longitudinal cohort study in 225 patients. Digestive and Liver Disease, 2017, 49, e28.	0.9	0

#	Article	IF	CITATIONS
253	Minimal increases of alpha-fetoprotein above the normal value strongly predict HCC development in compensated Caucasian HBV cirrhotics treated by entecavir or tenofovir: a 7-year longitudinal cohort study in 225 patients. Journal of Hepatology, 2017, 66, S689-S690.	3.7	O
254	Serum Markers for early diagnosis of hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virological response to direct-acting antivirals treatment. Journal of Hepatology, 2017, 66, S209-S210.	3.7	0
255	Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics. Digestive and Liver Disease, 2018, 50, 5.	0.9	0
256	Excellent 5-years survival for HBV cirrhotic patients developing a hepatocellular carcinoma during long-term analogs treatment. Digestive and Liver Disease, 2018, 50, 11.	0.9	0
257	Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Digestive and Liver Disease, 2018, 50, 14.	0.9	0
258	Predictors of hepatocellular recurrence after liver transplant in Hepatitis C patients: A ten-years single center cohort. Digestive and Liver Disease, 2018, 50, 54.	0.9	0
259	Multimodal and sequential treatment for hepatocellular carcinoma: How "real-life―complies with international recommendations. Digestive and Liver Disease, 2018, 50, 45.	0.9	0
260	Changes of AFP and PIVKA-II levels during DAA treatment and their predictive value for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment. Digestive and Liver Disease, 2018, 50, 49.	0.9	0
261	Baseline clinical features but not TLL1 variants predicts HCC onset in Caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years. Digestive and Liver Disease, 2018, 50, 51.	0.9	0
262	HCV treatment with DAA in patients listed for liver transplant does not result in an increased risk of HCC recurrence post-liver transplant. Journal of Hepatology, 2018, 68, S117-S118.	3.7	0
263	Clinical and genetic predictors of HCC occuring in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years. Journal of Hepatology, 2018, 68, S521-S522.	3.7	0
264	TLL1 variants do not predict the development of de-novo hepatocellular carcinoma in HCV cirrhotics treated with IFN-free DAA-based regimens. Journal of Hepatology, 2018, 68, S527.	3.7	0
265	Multimodal and sequential treatmente for hepatocellular carcinoma: how "real-life―complies with international recommendations. Journal of Hepatology, 2018, 68, S203.	3.7	0
266	The long-term risk and outcome of non-neoplastic portal vein thrombosis developing in compesated caucasian HBV cirrhotics treated with Tenofovir or Entecavir. Journal of Hepatology, 2018, 68, S521.	3.7	0
267	Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with Sorafenib. Journal of Hepatology, 2018, 68, S207-S208.	3.7	0
268	AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma. Digestive and Liver Disease, 2019, 51, e38.	0.9	0
269	Incidence and outcome of portal vein thrombosis in 817 HBV and HCV cirrhotic patients under antiviral treatment: a single center longitudinal study. Digestive and Liver Disease, 2019, 51, e10.	0.9	0
270	Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: safety and survival. Digestive and Liver Disease, 2019, 51, e35.	0.9	0

#	Article	IF	CITATIONS
271	The development of hepatolocellular carcinoma is not predicted by genetic variants in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 10 years. Digestive and Liver Disease, 2019, 51, e56.	0.9	0
272	FRI-474-AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e607.	3.7	0
273	The Authors' Reply. Transplantation, 2020, 104, e244-e244.	1.0	0
274	Low diagnostic accuracy of the AASLD radiologic criteria for hepatocellular carcinoma in grade I tumors Journal of Clinical Oncology, 2010, 28, e14606-e14606.	1.6	0
275	Diagnostic accuracy and standardization of fine needle biopsy in the characterization of liver nodules in cirrhosis Journal of Clinical Oncology, 2010, 28, e14576-e14576.	1.6	0
276	Comparison of field practice to registration trials of sorafenib in advanced HCC for effectiveness and tolerability Journal of Clinical Oncology, 2010, 28, e14637-e14637.	1.6	0
277	Natural history and multimodality treatment of early hepatocellular carcinoma prospectively detected in cirrhotic patients under surveillance Journal of Clinical Oncology, 2010, 28, e14574-e14574.	1.6	0
278	The natural history of hepatic macroregenerative nodules developing in cirrhotic patients during surveillance with ultrasound Journal of Clinical Oncology, 2010, 28, e14631-e14631.	1.6	0
279	Diagnosis and Stratification of Hepatocellular Carcinoma. , 2011, , 127-134.		0
280	An Unprecedented Challenge: The North Italian Gastroenterologist Response to COVID-19. Journal of Clinical Medicine, 2022, 11, 109.	2.4	0